Patent: 10,195,211
✉ Email this page to a colleague
Summary for Patent: 10,195,211
| Title: | Soft lozenge compositions |
| Abstract: | Described herein are topical, non-systemic, slow releasing oral pharmaceutical compositions, methods for making the same, and methods for treating subjects in need thereof with such compositions. In particular, the oral composition provides topical, non-systemic administration of one or more active pharmaceutical ingredients to the oral cavity and upper gastrointestinal track, including the esophagus. In one embodiment, the pharmaceutical composition provides topical corticosteroids to the esophagus and oral cavity. |
| Inventor(s): | Zhao; YinYan (Greensboro, NC), Hughey; Justin (Asheboro, NC), Vaughn; Jason (Browns Summit, NC), Fang; Qi (Oak Ridge, NC) |
| Assignee: | Patheon Softgels, Inc. (High Point, NC) |
| Application Number: | 15/795,846 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,195,211
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2035-06-15 |
| Genentech, Inc. | XOLAIR | omalizumab | For Injection | 103976 | 06/20/2003 | ⤷ Try a Trial | 2035-06-15 |
| Genentech, Inc. | XOLAIR | omalizumab | Injection | 103976 | 09/28/2018 | ⤷ Try a Trial | 2035-06-15 |
| Glaxosmithkline Llc | NUCALA | mepolizumab | For Injection | 125526 | 11/04/2015 | ⤷ Try a Trial | 2035-06-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
